Research location
Cromwell
Connecticut, United States
Advertisement
Research activity in Cromwell
Connecticut, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 53 trials and 53 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Cromwell
53 linked trials · page 1 of 2A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 · 2025-06-19 · 1 site observation
RECRUITING
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06963021 · 2025-05-30 · 1 site observation
RECRUITING
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06966401 · 2025-04-16 · 1 site observation
RECRUITING
A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379 · 2024-12-20 · 1 site observation
RECRUITING
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)NCT06633016 · 2024-09-20 · 1 site observation
RECRUITING
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 · 2025-09-02 · 1 site observation
ENROLLING_BY_INVITATION
An Open-Label Study of Azetukalner in Major Depressive DisorderNCT06922110 · 2025-03-18 · 1 site observation
ENROLLING_BY_INVITATION
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of SchizophreniaNCT06791122 · 2025-01-23 · 1 site observation
COMPLETED
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineNCT06280235 · 2024-03-27 · 1 site observation
COMPLETED
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419 · 2024-03-18 · 1 site observation
COMPLETED
Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World SettingNCT05956483 · 2023-12-04 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221 · 2023-09-22 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940 · 2023-08-09 · 1 site observation
COMPLETED
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of SchizophreniaNCT05838625 · 2023-03-31 · 1 site observation
COMPLETED
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)NCT05686408 · 2023-03-02 · 1 site observation
COMPLETED
Simufilam 100 mg for Mild-to-Moderate Alzheimer's DiseaseNCT04994483 · 2021-11-03 · 1 site observation
COMPLETED
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With DepressionNCT04521478 · 2020-11-20 · 1 site observation
COMPLETED
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive DisorderNCT04476030 · 2020-11-09 · 1 site observation
COMPLETED
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With SeltorexantNCT04533529 · 2020-09-16 · 1 site observation
COMPLETED
Open-Label Safety Study of AXS-05 in Subjects With DepressionNCT04039022 · 2019-07-08 · 1 site observation
COMPLETED
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT03968159 · 2019-04-25 · 1 site observation
COMPLETED
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)NCT03864614 · 2019-02-27 · 1 site observation
COMPLETED
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneNCT03739203 · 2018-11-10 · 1 site observation
COMPLETED
Addressing Dementia Via Agitation-Centered EvaluationNCT03226522 · 2017-07-13 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive DisorderNCT02741791 · 2016-03-01 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT02442765 · 2015-07-23 · 1 site observation
COMPLETED
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive DisorderNCT02288325 · 2014-11-18 · 1 site observation
COMPLETED
Safety and Efficacy of Vilazodone in Major Depressive DisorderNCT01573598 · 2012-04-01 · 1 site observation
COMPLETED
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyNCT01436175 · 2012-02-27 · 1 site observation
TERMINATED
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 HypertensionNCT01508026 · 2012-01-01 · 1 site observation
COMPLETED
Safety and Efficacy of Vilazodone in Major Depressive DisorderNCT01473381 · 2011-12-01 · 1 site observation
COMPLETED
Treatment of Neuropathic Pain Associated With Diabetic Peripheral NeuropathyNCT01496365 · 2011-11-28 · 1 site observation
COMPLETED
Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 HypertensionNCT01415505 · 2011-08-01 · 1 site observation
COMPLETED
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major DepressionNCT01361555 · 2011-08-01 · 1 site observation
TERMINATED
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major DepressionNCT01369095 · 2011-07-01 · 1 site observation
COMPLETED
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive DisorderNCT01377194 · 2011-06-01 · 1 site observation
COMPLETED
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderNCT01435759 · 2011-05-31 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)NCT01111539 · 2010-07-13 · 1 site observation
TERMINATED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01153347 · 2010-06-01 · 1 site observation
COMPLETED
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)NCT01121484 · 2010-06-01 · 1 site observation
COMPLETED
A Study in Depression and Associated Painful Physical SymptomsNCT01070329 · 2010-03-01 · 1 site observation
COMPLETED
Safety Study of F2695 SR in Major Depressive DisorderNCT01034267 · 2009-12-01 · 1 site observation
COMPLETED
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive DisorderNCT00985725 · 2009-10-29 · 1 site observation
COMPLETED
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderNCT00969709 · 2009-09-01 · 1 site observation
COMPLETED
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive DisorderNCT00863798 · 2009-04-01 · 1 site observation
COMPLETED
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal WomenNCT00406640 · 2006-12-01 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderNCT00411099 · 2006-12-01 · 1 site observation
COMPLETED
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic PainNCT00385671 · 2006-09-01 · 1 site observation
COMPLETED
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk ProgramNCT00401726 · 2006-06-01 · 1 site observation
COMPLETED
The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)NCT00279201 · 2005-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.